Table 1 Baseline characteristics of patients according to the presence/absence of PH or sICH
|  | No PH (n = 161) | PH (n = 28) | P | No sICH (n = 172) | sICH (n = 17) | P |
|---|---|---|---|---|---|---|
Age, years, mean (SD) | 64.1 ± 10.3 | 70.1 ± 10.5 | 0.005 | 64.6 ± 10.4 | 68.7 ± 11.7 | 0.133 |
Females, % | 59 (36.6) | 7 (25.0) | 0.233 | 60 (34.9) | 6 (35.3) | 0.973 |
Body mass index, kg/m2, mean (SD) | 24.4 ± 3.1 | 23.9 ± 3.0 | 0.401 | 24.4 ± 3.0 | 24.0 ± 3.5 | 0.601 |
Hypertension, % | 101 (62.7) | 21 (75.0) | 0.210 | 111 (64.5) | 11 (64.7) | 0.989 |
Diabetes, % | 50 (31.1) | 7 (25.0) | 0.519 | 51 (29.7) | 6 (35.3) | 0.629 |
Hyperlipidemia, % | 73 (45.3) | 12 (42.9) | 0.807 | 79 (45.9) | 6 (35.3) | 0.400 |
Previous stroke, % | 14 (8.7) | 5 (17.9) | 0.251 | 17 (9.9) | 2 (11.8) | 1.000 |
Coronary artery disease, % | 18 (11.2) | 5 (17.9) | 0.494 | 19 (11.0) | 4 (23.5) | 0.266 |
Atrial fibrillation, % | 48 (29.8) | 12 (42.9) | 0.171 | 50 (29.1) | 10 (58.8) | 0.012 |
Current smokers, % | 53 (32.9) | 8 (28.6) | 0.650 | 56 (32.6) | 5 (29.4) | 0.791 |
Ongoing antiplatelet therapy, % | 9 (5.6) | 7 (25.0) | 0.002 | 12 (7.0) | 4 (23.5) | 0.060 |
SBP, mm Hg, mean (SD) | 148.4 ± 18.4 | 154.5 ± 17.1 | 0.104 | 148.9 ± 18.2 | 153.2 ± 18.7 | 0.302 |
DBP, mm Hg, mean (SD) | 81.4 ± 9.8 | 83.2 ± 10.4 | 0.368 | 81.3 ± 9.7 | 84.8 ± 11.2 | 0.163 |
Blood glucose, mmol/L, median (IQR) | 7.2 (5.3–9.0) | 7.0 (5.8–9.5) | 0.133 | 7.0 (5.3–9.0) | 8.0 (5.5–9.5) | 0.645 |
Platelets, 109/L, mean (SD) | 187.9 ± 50.8 | 178.9 ± 40.0 | 0.371 | 187.3 ± 49.9 | 179.7 ± 44.5 | 0.545 |
INR, mean (SD) | 1.01 ± 0.08 | 1.01 ± 0.09 | 0.468 | 1.01 ± 0.08 | 1.03 ± 0.08 | 0.302 |
Baseline NIHSS, median (IQR) | 11 (6–15) | 17 (10–22.5) | 0.001 | 12 (6–15) | 13 (10–20) | 0.198 |
Onset to treatment, min, mean (SD) | 170.6 ± 48.8 | 183.4 ± 51.9 | 0.207 | 171.1 ± 48.9 | 187.2 ± 52.1 | 0.198 |
IV rtPA + endovascular therapy, % | 49 (30.4) | 9 (32.1) | 0.856 | 51 (29.7) | 7 (41.2) | 0.326 |